ESR1 and breast carcinoma: LEPR rs1137101 decreased ER+/PR+ breast cancer risk in the dominant genetic model (GA + AA vs. GG, adjusted OR = 0.727, 95% CI = 0.568–0.930, p = 0.011) and the co-dominant genetic model (GA vs. GG, adjusted OR = 0.739, 95% CI = 0.575–0.951, p = 0.019).